Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Age > 18 years
Diagnosis of primary open angle glaucoma
Willing and able to give informed consent
Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use
Pregnancy
Prisoners
Known allergy or sensitivities to brimonidine
No surgery within the past 6 months